201 related articles for article (PubMed ID: 14643383)
1. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.
Li L; Fan M; Icton CD; Chen N; Leavitt BR; Hayden MR; Murphy TH; Raymond LA
Neurobiol Aging; 2003 Dec; 24(8):1113-21. PubMed ID: 14643383
[TBL] [Abstract][Full Text] [Related]
2. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
Li L; Murphy TH; Hayden MR; Raymond LA
J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
4. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
[TBL] [Abstract][Full Text] [Related]
5. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
6. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.
Fan MM; Fernandes HB; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2007 Apr; 27(14):3768-79. PubMed ID: 17409241
[TBL] [Abstract][Full Text] [Related]
7. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
Milnerwood AJ; Raymond LA
J Physiol; 2007 Dec; 585(Pt 3):817-31. PubMed ID: 17947312
[TBL] [Abstract][Full Text] [Related]
8. NMDA receptor function in mouse models of Huntington disease.
Cepeda C; Ariano MA; Calvert CR; Flores-Hernández J; Chandler SH; Leavitt BR; Hayden MR; Levine MS
J Neurosci Res; 2001 Nov; 66(4):525-39. PubMed ID: 11746372
[TBL] [Abstract][Full Text] [Related]
9. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
10. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
Zeron MM; Hansson O; Chen N; Wellington CL; Leavitt BR; Brundin P; Hayden MR; Raymond LA
Neuron; 2002 Mar; 33(6):849-60. PubMed ID: 11906693
[TBL] [Abstract][Full Text] [Related]
11. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
12. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease.
Heng MY; Detloff PJ; Wang PL; Tsien JZ; Albin RL
J Neurosci; 2009 Mar; 29(10):3200-5. PubMed ID: 19279257
[TBL] [Abstract][Full Text] [Related]
13. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
14. Mutant huntingtin enhances excitotoxic cell death.
Zeron MM; Chen N; Moshaver A; Lee AT; Wellington CL; Hayden MR; Raymond LA
Mol Cell Neurosci; 2001 Jan; 17(1):41-53. PubMed ID: 11161468
[TBL] [Abstract][Full Text] [Related]
15. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
[TBL] [Abstract][Full Text] [Related]
16. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
Kolodziejczyk K; Raymond LA
Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease.
Zeron MM; Fernandes HB; Krebs C; Shehadeh J; Wellington CL; Leavitt BR; Baimbridge KG; Hayden MR; Raymond LA
Mol Cell Neurosci; 2004 Mar; 25(3):469-79. PubMed ID: 15033175
[TBL] [Abstract][Full Text] [Related]
18. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
19. PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity.
Puddifoot C; Martel MA; Soriano FX; Camacho A; Vidal-Puig A; Wyllie DJ; Hardingham GE
J Neurosci; 2012 May; 32(20):6995-7000. PubMed ID: 22593067
[TBL] [Abstract][Full Text] [Related]
20. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
Graham RK; Pouladi MA; Joshi P; Lu G; Deng Y; Wu NP; Figueroa BE; Metzler M; André VM; Slow EJ; Raymond L; Friedlander R; Levine MS; Leavitt BR; Hayden MR
J Neurosci; 2009 Feb; 29(7):2193-204. PubMed ID: 19228972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
